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ABSTRACT
In mammalian cells, DNA damage induces robust
changes in gene expression and these changes
contribute to the proper execution of cellular responses
to DNA damage, including DNA repair, cell cycle arrest
and apoptosis. The transcription factor E2F-1 has been
suggested to play a key role in the regulation of cell
cycle-dependent gene expression and apoptosis.
These activities depend on the ability of E2F-1 to form
functionally active DNA binding complexes. Here we
describe an assay that allows one to measure E2F-1
DNA binding activity in naive cells. We find that DNA
damage, generated by UV- or γ-irradiation, prompts
increased production of E2F-1 DNA binding activity,
which, at least in part, originates from alterations in
E2F-1 protein levels. These findings represent an
indication for a role of the transcription factor E2F-1 in
the DNA damage response pathway.
INTRODUCTION
Mammalian cells have evolved a complex, multifaceted network
through which DNA damage is detected and an appropriate
response is implemented (1). These cellular responses to
damaged DNA represent defenses against genomic instability
and tumorigenesis resulting from unrepaired damage (2). DNA
damage inflicted by radiation (or by genotoxic drugs) is detected
by a dedicated DNA damage-sensing apparatus which then
generates a signal that can lead to DNA repair, cell cycle arrest
and apoptosis. Which fate prevails depends on the severity of the
damage and the type of cell affected. The signal transduction
system, which communicates information between a DNA lesion
and components of the cell cycle, is referred to as the DNA
damage checkpoint (1).
In mammalian cells, the p53 tumor suppressor is the archetype
of known DNA damage checkpoint regulators. p53 is stabilized
and activated as a transcription factor following genomic DNA
damage and under such circumstances provides a crucial block to
cell cycle progression, leading to growth arrest (to allow time for
repair processes) or apoptosis (3). Because p53 is mutated in a
large fraction of cancers of diverse types, it is thought that the
tumorigenic process may be intimately related to the disruption
of p53-mediated control of the cell cycle. The precise signal
transduction pathway that senses DNA damage and recruits p53
has not been elucidated, but it is likely to include ATM, a member
of the PI3 kinase-related protein kinase superfamily, as well as
other proteins known to be critical regulators of the cellular
response to DNA damage, such as c-abl and CHK1 (1).
E2F, a family of heterodimeric transcription factors composed
of E2F-like and DP-like subunits, is crucial for transcriptional
activation of genes that regulate S phase entry and genes that
function to engage DNA synthesis (4). E2F-1, the first cloned
member of this family, plays a key role in the regulation of cell
proliferation and apoptosis. Overexpression of E2F-1 can cause
oncogenesis (5–7) and is sufficient to drive serum-starved
fibroblasts into S phase (8–11). In some settings, prolonged
expression of E2F-1 drives cells also to undergo p53-dependent
or p53-independent apoptosis (9–15). Recent observations,
derived from studies on mice homozygous for a non-functional
E2F-1 allele, strongly suggest that E2F-1 has a tumor suppression
function as well, which might be linked to its apoptosis-inducing
activity (16,17). Despite the evidence that E2F-1 is a key
participant in the regulation of cell cycle progression and
apoptosis, no information exists about a potential sensitivity of
E2F-1 activity to DNA damage. Here we report on an assay that
we have developed allowing one to monitor the DNA binding
activity of endogenous E2F-1. We find that two distinct DNA
damaging agents, UV- and γ-irradiation, trigger the production of
increased amounts of DNA binding competent E2F-1, implying
that E2F-1 participates in the DNA damage response pathway.
MATERIALS AND METHODS
Cell culture, radiation treatment and cell cycle analysis
Human U2-OS and T98G cells were maintained and synchronized
by serum deprivation as described previously (18). At indicated
time points after release from serum deprivation, tissue culture
dishes receiving radiation treatment were exposed to UV-C
(Stratalinker 1800 UV crosslinker; Stratagene, La Jolla, CA) or
γ-rays (using a 60Co source). For UV-irradiation of cells, the
culture medium was aspirated, cells were washed once with
phosphate-buffered saline (PBS) and uncovered tissue culture
plates were irradiated with 20 J/m2. Afterwards, culture medium
was added back to the cells. For γ-irradiation, cells were directly
exposed to a dose of 6 Gy, without removing the medium. For
control, the same procedure was followed as described above,
except that cells were not exposed to radiation. Typically, cells
were 50–80% confluent at the time of irradiation and were
harvested 1 h after treatment by trypsinization. Cell cycle
progression was monitored by flow cytometry as described (18).
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Antibodies
For the production of peptide antibodies recognizing human E2F-1,
the peptide ALGRPPVKRRLDLETDHQYL, corresponding to a
region in E2F-1 spanning amino acid residues 82–101, was
synthesized. The peptide was coupled to keyhole limpet hemo-
cyanin (Pierce) by glutaraldehyde coupling and injected into
rabbits. Anti-peptide antibodies were affinity purified by coupling
10 mg peptide to 1 g CH-Sepharose 4B (Pharmacia) according to
the manufacturer’s protocol. Incubation and elution of the
antibody, referred to as anti-E2F-1(N), was carried out as
described (18). The mouse monoclonal antibody (mAb) E2F-1
Powerclonal (PC), recognizing human E2F-1, was purchased
from Upstate Biotechnology. The affinity purified rabbit polyclonal
peptide antibodies E2F-1(C20)X [referred to in the manuscript as
anti-E2F-1(C)] and E2F-4(C20) recognizing the C-termini of
human E2F-1 and E2F-4, respectively, were obtained from Santa
Cruz Biotechnology. Anti-cyclin A antibodies raised against
full-length human cyclin A have been described previously (18).
Whole cell extracts and immunoblotting
For whole cell extract preparation, cells were washed twice in
PBS and lysed in extraction buffer (20 mM HEPES, pH 7.9, 0.5%
NP-40, 1 mM EDTA, 0.4 M NaCl, 25% glycerol, 10 mM NaF,
0.1% NP-40, 1 mM DTT, 1 mg/ml aprotinin, 1 mM PMSF) for
30 min on ice. Extracts were clarified by centrifugation and
quantitated with the BioRad protein assay reagent kit. Immuno-
blotting was performed according to published procedures (18).
Antibody detection was achieved by enhanced chemiluminescence
(ECL; Amersham).
Immunoprecipitation, peptide release assay and EMSA
For immunoprecipitation, 80% confluent T98G or U2-OS cells in
a 10 cm dish were lysed in 800 µl TNN buffer (50 mM Tris–HCl,
pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.5% NP-40,
1 mM DTT, 1 mg/ml aprotinin, 1 mM PMSF) and incubated on
ice for 30 min. Extracts were clarified by centrifugation,
quantitated with the BioRad protein assay reagent kit and
equalized amounts of cell protein were subjected to immuno-
precipitation with 1.5 µg of the indicated antibodies. For peptide
competition experiments, antibodies were preincubated with 2 µg
of the corresponding peptide for 15 min at 4C. Protein
A–Sepharose was added, immune complexes were collected by
centrifugation and washed four times with TNN buffer and once
with gel shift buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 10 mM
MgCl2, 10% glycerol, 0.1% NP-40, 0.1 mM EDTA, 0.5 mM
DTT). To disrupt antibody–antigen interactions, washed immune
complexes were incubated with gel shift buffer containing 2 mg/ml
competing peptide at 4C for 10 min. Subsequently, samples
were centrifuged at 14 000 g at 4C for 10 min, supernatants were
collected, transferred into fresh Eppendorf tubes and directly used
in electrophoretic mobility shift assays (EMSAs) (19). For
antibody supershifts, 1 µg of indicated antibodies were added to
binding reactions prior to the addition of labeled E2F oligo-
nucleotide. For competition, a 100-fold molar excess of unlabeled
E2F oligonucleotide was added to the gel shift assay. The
sequence of the E2F oligonucleotide corresponds to the DHFR
promoter and has been described (19).
Figure 1. Measurement of endogenous E2F-1 DNA binding activity. T98G
cells were growth arrested by serum deprivation and stimulated to re-enter the
cell cycle by serum addition. Twenty two hours after serum stimulation
(corresponding to early S phase), whole cell extracts were prepared and
processed for immunoprecipitation with either anti-E2F-1(C) antibody
(lanes 1–5) or anti-E2F-1(N) antibody (lanes 6–10) in the absence (lanes 1–4
and 6–9) or presence (lanes 5 and 10) of the corresponding immunizing
peptides. Immunecomplexes were collected with protein A–Sepharose and
treated with the corresponding immunizing peptides, as indicated at the  top of
the figure, to interrupt antibody–antigen interaction. The resultant supernatants
were analyzed by EMSA assay for E2F DNA binding activity in the presence
of either anti-E2F-1(N) antibody (lane 4) or anti-E2F-1 mAb PC (lane 9).
Competition experiments were done with oligonucleotides containing either a
wild-type (lanes 2 and 7) or a mutant (lanes 3 and 8) E2F site derived from the
dihydrofolate reductase (DHFR) promoter.
RESULTS AND DISCUSSION
The abundance of E2F-1 is relatively low in multiple cell lines
and hence, it has proven difficult in the past to measure
specifically E2F-1 DNA binding activity in whole cell extracts
without the use of transfection technology. We attempted to
devise an assay that allows one to monitor selectively E2F-1 DNA
binding activity. To this end, anti-E2F-1 immunoprecipitates were
generated from whole cell extracts derived from T98G cells that
had been previously synchronized in late G1/early S phase (a time
where E2F-1 expression is highest) using peptide antibodies
raised to distinct epitopes of human E2F-1. Antibody–antigen
interactions were resolved by treatment of immune complexes
with the relevant immunizing peptide (referred to as C-peptide
and N-peptide) and supernatants were tested in gel shift assays.
As shown in Figure 1, anti-E2F-1(C) or anti-E2F-1(N) immuno-
precipitates contained E2F gel shift activity (lanes 1 and 6,
respectively). This activity was absent when the C- or N-peptide was
added to the corresponding antibody prior to immunoprecipitation
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Figure 2. Effect of UV-irradiation on E2F-1 DNA binding activity. (A) Exponentially growing T98G or U2-OS cells were either left untreated (lanes 1 and 3) or were
treated with 20 J/m2 UV-irradiation (lanes 2 and 4) followed by an incubation period of 1 h. Whole cell extracts were prepared and processed for E2F-1 IP gel shift
assay as described in Figure 1 using anti-E2F-1(C) antibody. Note the increase in immunoprecipitable E2F-1-specific DNA binding activity in response to DNA
damage. (B) T98G cells were growth arrested by serum deprivation and stimulated to re-enter the cell cycle by serum addition. At indicated times after serum
stimulation, cells were either left untreated (lanes 1, 3, 5 and 7) or were treated with the indicated dose of UV (lanes 2, 4, 6 and 8). Whole cell extracts were prepared,
corrected for total protein amounts and processed for E2F-1 IP gel shift assay immunoprecipitation with anti-E2F-1(N) antibody. The autoradiogram shown is a
representative of multiple independently performed experiments. (C) E2F-1 gel shift activities shown in (A) were densitometrically traced. The E2F-1 DNA binding activity
detected at 17 h after serum addition (lane 1) was set to 1 and used to normalize the signal at the subsequent time points. (D) Cells harvested in (A) either before (upper panel)
or after (lower panel) UV-irradiation were fixed in 70% ethanol, stained with propidium iodide and subjected to flow cytometric analysis to determine cell cycle distribution.
(lanes 5 and 10, respectively). Competition experiments indicated
that the observed DNA binding activity was E2F-specific (Fig. 1,
lanes 2, 3, 7 and 8). Moreover, the recovered E2F gel shift activity
was supershifted by anti-E2F-1(N) antibody (lane 4) or by
anti-E2F-1 mAb PC (lane 9). Taken together, these data suggest
that the procedure employed here permits the specific and
selective recovery of E2F-1 DNA binding activity from whole
cell extracts of naive cells. For simplicity we refer to this whole
procedure as the E2F-1 immunoprecipitation (IP) gel shift assay.
The absence of a RB/E2F-1 gel shift complex can be explained
by the fact that in this particular experiment early S phase
synchronized T98G cells were used. At that time pRB is
hyperphosphorylated and unable to bind E2F-1. Using the very
same procedure, we did, however, recover an RB/E2F-1 gel shift
complex from asynchronously growing T98G cells (Fig. 2A,
lanes 1 and 2).
There is abundant evidence that E2F-1 plays a critical role in
normal cell cycle regulation. However, there is little evidence that
indicates a role of E2F-1 in the cellular response to DNA damage.
Thus, we asked whether the DNA binding activity of E2F-1
changes in response to DNA damage. Exponentially growing
T98G and U2-OS cells were exposed to UV at a dose of 20 J/m2
and harvested 1 h later. E2F-1 IP gel shift analysis of unperturbed
control cells revealed the presence of one major, faster migrating
band corresponding to ‘free’ E2F-1 (Fig. 2A, lanes 1and 3) and
one minor, slower migrating band (Fig. 2A, lane 1). The slower
migrating gel shift activity contains pRB, since it was specifically
supershifted by anti-pRB antibody (data not shown). The absence
of an RB/E2F-1 gel shift activity in U2-OS cells is likely due to
the fact that exponentially growing U2-OS cells contain little, if
any, underphosphorylated pRB. Strikingly, UV treatment led to
a significant increase in E2F-1 immunoprecipitable gel shift
activity in both cell lines (Fig. 2A, lanes 2 and 4). The simplest
model to explain this observation would be one in which DNA
damage, produced by UV, triggers a signaling cascade, one
outcome of which is increased levels of E2F-1 DNA binding
activity.
The expression of E2F-1 protein is periodic, peaking in
early/mid S phase and then decaying as cells progress into the late
S/G2 phases (20). Thus, we asked whether UV can effect E2F-1
DNA binding activity at all times during G1 and S phase
progression. To this end, T98G cells were synchronized by serum
deprivation in G0/G1, released from the arrest by the addition of
serum and at indicated time points IP gel shift assays were
performed, in parallel, from untreated cells or from cells treated
with UV at a dose of 20 J/m2 as a stimulus. Cell synchrony was
monitored in parallel by flow cytometry (Fig. 2D). Cells released
into early S phase (17 and 18 h after serum addition) contained
significant amounts of E2F-1 gel shift activity (Fig. 2B, lanes 1
and 3). E2F-1 DNA binding activity decayed as cells progressed
further into the S and G2 phases (Fig. 2B, lanes 5 and 7,
respectively), consistent with earlier results that linked the
disapperance of E2F-1 DNA binding function in late S/G2 to the
apperance of cyclin A kinase at that time (21–23). Like the effect
seen before in exponentially growing cells, UV treatment led to
a significant (∼3-fold) increase in E2F-1 DNA binding activity at
all stages throughout S phase (Fig. 2B and C). Similar results were
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Figure 3. Activation of E2F-1 DNA binding function by γ-irradiation.
(A) T98G cells were synchronized and processed exactly as described in the
legend to Figure 2B, except that at indicated time points cells were exposed to
6 Gy of γ-irradiation instead of UV. (B) E2F-1 DNA binding activity shown in
(A) was quantified as described in Figure 2C.
obtained when cell synchrony was achieved by mimosine or
hydroxyurea block release (data not shown).
To determine whether other types of DNA damaging agents, in
particular γ-irradiation, produce a similar increase in E2F-1 DNA
binding activity, early S phase synchronized T98G cells were
either left untreated or were treated with γ-irradiation at a dose of
6 Gy and subjected to the E2F-1 IP gel shift assay. Similar to the
results obtained with UV, γ-irradiation led to an ∼3-fold increase
in immunoprecipitable E2F-1 DNA binding activity compared
with untreated control cells (Fig. 3A and B, compare lanes 2 and
4 with 1 and 3). These results collectively suggest that the
responses provoked by these two distinct DNA damaging agents
involve an increase in E2F-1 DNA binding function.
The significance of these observations arises from the fact that
to date, all biological activities of E2F-1 depend on its ability to
function as a sequence-specific DNA binding element. Thus, with
the observation that the amount of E2F-1 DNA binding activity
increases significantly in response to distinct types of DNA
damage, it seems fair to conclude that increased amounts of
E2F-1 DNA binding activity affect the expression of one or more
genes at the level of transcription. Indeed, existing evidence
suggests that the expression of at least one known target gene of
E2F, ribonucleotide reductase (RNR), is up-regulated in response
to DNA damage (24). RNR catalyzes the direct reduction of
ribonucleotides to the corresponding deoxyribonucleotides,
thereby providing the necessary precursors for DNA replication
and efficient DNA repair. Given the results shown in this report,
one might speculate that E2F-1 contributes, at least in part, to the
activation of RNR transcription in response to DNA damage,
thereby facilitating efficient DNA repair. At present, we cannot
determine whether the increase in E2F-1 DNA binding activity in
response to DNA damage reported here also translates into
enhanced transactivation function of E2F-1. However, this is
difficult to test because E2F reporter assays allow one to measure
the collective activity of E2F only. Finally, a role for E2F-1 in the
enaction of DNA damage checkpoint responses may be related to
its apoptosis-inducing activities. At least in certain experimental
settings, it was shown that the induction of apoptosis by E2F-1
does not require its transactivation function but is dependent on
the ability of E2F-1 to bind DNA (14,15). Given these results and
those shown here, one can imagine that the increase in E2F-1
DNA binding activity seen in response to DNA damage could
directly translate into an enhanced tendency of damaged cells to
undergo apoptosis.
E2F-1 function is controlled at multiple levels, including at the
level of transcription, turnover, phosphorylation and interactions
with other proteins (4). In an effort to understand the mechanism
underlying the increase in E2F-1 DNA binding activity in
response to DNA damage, we examined whether there might be
changes in the levels of E2F-1 protein as a consequence of DNA
damage checkpoint activation. T98G cells were synchronized
and treated with UV- or γ-irradiation as before and whole cell
extracts were prepared and analyzed by immunoblotting using
antibodies specific for E2F-1. Exposure of T98G cells to either
UV- or γ-irradiation was found to markedly increase the levels of
E2F-1 protein compared with untreated cells (Fig. 4A and B,
upper panel, respectively). No such effect was seen for either
cyclin A (Fig. 4A, lower) or E2F-4 (Fig. 4B, lower panel) when
analyzed in parallel. These data suggest that the increase in E2F-1
protein levels in response to DNA damaging agents employed
here is specific. In addition, these results suggest a relationship
between the DNA damage-associated increase in E2F-1 protein
levels and an increase in E2F-1-dependent DNA binding activity, at
least in the cell types under investigation. However, we cannot
exclude other mechanisms, e.g. phosphorylation/dephosphorylation
reactions, which might contribute, in part, to the rise in E2F-1
DNA binding activity after DNA damage. In addition, whether
the increase in E2F-1 protein levels observed here is a result of
enhanced transcription of the E2F-1 gene itself or is a reflection
of an increase in E2F-1 protein stability, or both, remains to be
determined. However, there are certainly interesting parallels
between these observations and the known relationship between
p53 and DNA damage. Specifically, p53 protein is stabilized in
response to various DNA damaging agents and this stabilization
appears to result from reduced p53 ubiquitination (25). E2F-1,
too, is regulated by ubiquitin-mediated proteolysis (26–28).
However, the relevant components mediating E2F-1 turnover
have not yet been elucidated. It will be possible to investigate this
issue only when the mechanism underlying E2F-1 degradation is
fully understood.
The observations reported here imply E2F-1 as a participant in
the DNA damage response pathway. Further exploration of this
pathway should help to elucidate how the DNA damage-associated
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Figure 4. DNA damage-induced increase in E2F-1 protein levels. (A and B)
Aliquots of whole cell extracts of T98G cells analyzed in Figures 2B and 3A for
E2F-1 DNA binding activity were subjected to immunoblot analysis using
either anti-E2F-1 mAb PC (upper panel), anti-cyclin A antibodies (A, lower
panel) or E2F-4 antibodies (B, lower panel). Note the relative increase in E2F-1
protein levels compared with control in response to DNA damage.
increase in E2F-1 DNA binding activity is linked to the behavior
of at least some of the known regulators of the DNA damage
checkpoint.
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